Fate Therapeutics (NASDAQ:FATE)

I admit there was a bit of FOMO going on when I green-thumbed this stock. I think it was the big words that impressed me most. Pluri-potent stem cells. How can you not want to open your wallet and just start dishing it out? While my lack of DD is apparent, I can say that I'm impressed with a couple of things. One is the number of candidates FATE has in the pipeline. The other is that many of these candidates try to attack more than one weakness on a cancer cell. FT596 is a good example. The problem with attacking a single site is that the cell line has a tendency to work around that attack. You may have initial good results, but the surviving cells then produce more cells resistant to that drug. You can use combo therapy or a drug that targets more than one site on the cancer cell. FATE is doing both. I get excited when I see this and tend to green-thumb stuff before I really know enough to make an informed decision. Take that into consideration.

From 12/09/2019:

"In total, Fate Therapeutics has 13 different programs in various stages of development. Whether that means the company lacks focus or has many shots on goal, Wall Street appears to be waiting for more concrete evidence that any of its drug candidates actually work. Given the tumbling stock price and a market valuation of only $1 billion, the risk-reward presented by this small-cap biotech stock could turn a small position into a long-term stroke of genius for patient investors."

https://www.fool.com/investing/2019/12/09/2-top-biotech-stocks-to-buy-in-december.aspx